Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Tuesday, January 17, 2023
Avacta Group, a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics announces that AVA6000 continues to show a very favourable safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation ...
read more
Thursday, October 29, 2015
Capsugel has announced the global commercial launch of its enTRinsicTM drug delivery technology platform.
read more
Tuesday, February 28, 2017
The Cryoport Biotech Regenerative Therapy Activity Index (the "CoBRA IndexSM") quantifies the activity in the development and clinical trials of regenerative therapies in the United States, and acts as a means by which investors, the media and ...
read more
Aceto, a global provider of specialty materials for life sciences and advanced technology end markets, has announced the acquisition of a majority stake in Finar Limited.
read more
QPS continues to expand and align its full service preclinical, bioanalysis and clinical capabilities with enhanced offerings across the medical, regulatory and biotech divisions.
read more
PierianDx announced a strategic partnership with RTI International to help solve the problem of translating complex genomic data into actionable clinical insight to advance precision medicine
read more
Thursday, October 18, 2012
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has been selected by AstraZeneca (NYSE: AZN) as its preferred strategic partner for outsourced regulated safety assessment and development DMPK (drug metabolism and ...
read more
A novel ophthalmic solution from R-Tech Ueno (Tokyo, Japan) made using Novozymes Biopharma’s recombinant human albumin has recently obtained FDA approval to undergo Phase I/II clinical trials in the United States.
read more
Wednesday, November 18, 2015
PAREXEL International Corporation has announced the enhancement of its end-to-end clinical development services through its new process, called Clinical Development Optimization.
read more
Catalent announced that it has expanded its integrated development, manufacturing and supply solution, OneBio® Suite, across a range of biologic modalities, including antibody and recombinant proteins, cell and gene therapies, and mRNA.
read more
Validant, a leading global quality, compliance and regulatory consulting group, has acquired Clinical Outcomes Solutions (COS), a global leader in clinical outcomes assessments (COA). COS was founded in 2013 and has developed a leadership position in...
read more
Teva Pharmaceutical Industries has agreed to sell assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Limited (a subsidiary of Intas Pharmaceuticals Ltd) for an agreed value of GBP 603 million, subject to final ...
read more
Monday, December 18, 2017
Ionis announced its license agreement with Roche to develop and commercialize IONIS-HTTRx has received clearance under the Hart-Scott-Rodino Antitrust Improvements Act.
read more
Tuesday, February 03, 2015
Following 16 months of construction, the first phase of a modern, multi-functional building at Vetter’s Ravensburg Schuetzenstrasse site has been completed. Estimated to be fully operational by the beginning of 2016, the new facility will contain ...
read more
Jazz Pharmaceuticals announced a definitive agreement to sell its rights related to Prialt intrathecal infusion to TerSera Therapeutics for $80 million in cash at closing.
read more